Jump to content

Samidorphan: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Citation bot (talk | contribs)
Bots
5,388,536 edits
Add: doi-access. | Use this bot. Report bugs. | #UCB_CommandLine
Add link to and explain acronym.
Line 49: Line 49:
Samidorphan has been investigated for the treatment of [[alcoholism]] and [[cocaine addiction]] by its developer, [[Alkermes (company)|Alkermes]],<ref>{{cite journal | vauthors = Hillemacher T, Heberlein A, Muschler MA, Bleich S, Frieling H | title = Opioid modulators for alcohol dependence | journal = Expert Opinion on Investigational Drugs | volume = 20 | issue = 8 | pages = 1073–1086 | date = August 2011 | pmid = 21651459 | doi = 10.1517/13543784.2011.592139 | s2cid = 43338618 }}</ref><ref>{{ClinicalTrialsGov|NCT01366001|ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With Cocaine}}</ref> showing similar efficacy to [[naltrexone]] but possibly with reduced [[side effect]]s.
Samidorphan has been investigated for the treatment of [[alcoholism]] and [[cocaine addiction]] by its developer, [[Alkermes (company)|Alkermes]],<ref>{{cite journal | vauthors = Hillemacher T, Heberlein A, Muschler MA, Bleich S, Frieling H | title = Opioid modulators for alcohol dependence | journal = Expert Opinion on Investigational Drugs | volume = 20 | issue = 8 | pages = 1073–1086 | date = August 2011 | pmid = 21651459 | doi = 10.1517/13543784.2011.592139 | s2cid = 43338618 }}</ref><ref>{{ClinicalTrialsGov|NCT01366001|ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With Cocaine}}</ref> showing similar efficacy to [[naltrexone]] but possibly with reduced [[side effect]]s.


However, it has attracted much more attention as part of the [[combination drug|combination product]] [[ALKS-5461]] (buprenorphine/samidorphan), where samidorphan is combined with the mixed MOR weak [[partial agonist]] and [[κ-opioid receptor]] (KOR) antagonist [[buprenorphine]], as an [[antidepressant]]. Buprenorphine has shown antidepressant effects in some human studies, thought to be because of its antagonist effects at the KOR, but has not been further developed for this application because of its MOR agonist effects and consequent [[abuse potential]]. By combining buprenorphine with samidorphan to block the MOR agonist effects, the combination acts more like a selective KOR antagonist, and produces only antidepressant effects, without typical MOR effects such as [[euphoria]] or [[substance dependence]] being evident.<ref>{{cite web | url = https://www.clinicaltrialsarena.com/uncategorized/newsalks-5461-reduce-depressive-study/ | title = ALKS 5461 drug found to reduce depressive symptoms in Phase 1/2 study | date = 30 May 2012 }}</ref><ref>{{cite web | url = http://infoviewer.biz/infodisplay/story/imn062020121658153330.html?APP=7&CU=imn5804 | title = Investigational ALKS 5461 Channels 'Opium Cure' for Depression }}</ref>
However, it has attracted much more attention as part of the [[combination drug|combination product]] [[ALKS-5461]] (buprenorphine/samidorphan), where samidorphan is combined with the mixed [[μ-opioid receptor]] (MOR) weak [[partial agonist]] and [[κ-opioid receptor]] (KOR) antagonist [[buprenorphine]], as an [[antidepressant]]. Buprenorphine has shown antidepressant effects in some human studies, thought to be because of its antagonist effects at the KOR, but has not been further developed for this application because of its MOR agonist effects and consequent [[abuse potential]]. By combining buprenorphine with samidorphan to block the MOR agonist effects, the combination acts more like a selective KOR antagonist, and produces only antidepressant effects, without typical MOR effects such as [[euphoria]] or [[substance dependence]] being evident.<ref>{{cite web | url = https://www.clinicaltrialsarena.com/uncategorized/newsalks-5461-reduce-depressive-study/ | title = ALKS 5461 drug found to reduce depressive symptoms in Phase 1/2 study | date = 30 May 2012 }}</ref><ref>{{cite web | url = http://infoviewer.biz/infodisplay/story/imn062020121658153330.html?APP=7&CU=imn5804 | title = Investigational ALKS 5461 Channels 'Opium Cure' for Depression }}</ref>


Samidorphan was also studied in combination with [[olanzapine]], as ALKS-3831 ([[olanzapine/samidorphan]]), for use in [[schizophrenia]].<ref>{{cite news | first = John | last = LaMattina | name-list-style = vanc | date = 15 January 2013 |url = https://www.forbes.com/sites/johnlamattina/2013/01/15/will-alkermes-antipsychotic-alks-3831-become-another-tredaptive/|title = Will Alkermes' Antipsychotic ALKS-3831 Become Another Tredaptive? |work = Forbes}}</ref> A Phase 3 study found that the addition of samidorphan to olanzapine significantly reduced weight gain compared to olanzapine alone,<ref>{{cite journal | vauthors = Correll CU, Newcomer JW, Silverman B, DiPetrillo L, Graham C, Jiang Y, Du Y, Simmons A, Hopkinson C, McDonnell D, Kahn RS | display-authors = 6 | title = Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study | journal = The American Journal of Psychiatry | volume = 177 | issue = 12 | pages = 1168–1178 | date = December 2020 | pmid = 32791894 | doi = 10.1176/appi.ajp.2020.19121279 | s2cid = 221122225 }}</ref> and the combination was approved for the treatment of schizophrenia and [[bipolar disorder]] by the US [[Food and Drug Administration]] in May 2021, under the brand name [[olanzapine/samidorphan|Lybalvi]].<ref>{{cite web | title=Lybalvi: FDA-Approved Drugs | website=U.S. [[Food and Drug Administration]] (FDA) | url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213378 | access-date=1 June 2021}}</ref><ref>{{Cite news|last= Ergenzinger|first=Ed|title=New Antipsychotic Combo for Bipolar Disorder Approved by FDA {{!}} Psychology Today|url=https://www.psychologytoday.com/us/blog/night-sweats-and-delusions-grandeur/202106/new-antipsychotic-combo-bipolar-disorder-approved|access-date=2021-07-24|work=www.psychologytoday.com|language=en}}</ref>
Samidorphan was also studied in combination with [[olanzapine]], as ALKS-3831 ([[olanzapine/samidorphan]]), for use in [[schizophrenia]].<ref>{{cite news | first = John | last = LaMattina | name-list-style = vanc | date = 15 January 2013 |url = https://www.forbes.com/sites/johnlamattina/2013/01/15/will-alkermes-antipsychotic-alks-3831-become-another-tredaptive/|title = Will Alkermes' Antipsychotic ALKS-3831 Become Another Tredaptive? |work = Forbes}}</ref> A Phase 3 study found that the addition of samidorphan to olanzapine significantly reduced weight gain compared to olanzapine alone,<ref>{{cite journal | vauthors = Correll CU, Newcomer JW, Silverman B, DiPetrillo L, Graham C, Jiang Y, Du Y, Simmons A, Hopkinson C, McDonnell D, Kahn RS | display-authors = 6 | title = Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study | journal = The American Journal of Psychiatry | volume = 177 | issue = 12 | pages = 1168–1178 | date = December 2020 | pmid = 32791894 | doi = 10.1176/appi.ajp.2020.19121279 | s2cid = 221122225 }}</ref> and the combination was approved for the treatment of schizophrenia and [[bipolar disorder]] by the US [[Food and Drug Administration]] in May 2021, under the brand name [[olanzapine/samidorphan|Lybalvi]].<ref>{{cite web | title=Lybalvi: FDA-Approved Drugs | website=U.S. [[Food and Drug Administration]] (FDA) | url=https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213378 | access-date=1 June 2021}}</ref><ref>{{Cite news|last= Ergenzinger|first=Ed|title=New Antipsychotic Combo for Bipolar Disorder Approved by FDA {{!}} Psychology Today|url=https://www.psychologytoday.com/us/blog/night-sweats-and-delusions-grandeur/202106/new-antipsychotic-combo-bipolar-disorder-approved|access-date=2021-07-24|work=www.psychologytoday.com|language=en}}</ref>

Revision as of 05:23, 4 February 2024

Samidorphan
Clinical data
Other namesALKS-33; RDC-0313; 3-Carboxamido-4-hydroxynaltrexone
Routes of
administration		Oral
Pharmacokinetic data
Elimination half-life7–9 hours[1][2]
Identifiers
  • 17-(Cyclopropylmethyl)-4,14-dihydroxy-6-oxomorphinan-3-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H26N2O4
Molar mass370.449 g·mol−1
3D model (JSmol)
  • c1cc(c(c2c1C[C@@H]3[C@]4([C@]2(CCN3CC5CC5)CC(=O)CC4)O)O)C(=O)N
  • InChI=1S/C21H26N2O4/c22-19(26)15-4-3-13-9-16-21(27)6-5-14(24)10-20(21,17(13)18(15)25)7-8-23(16)11-12-1-2-12/h3-4,12,16,25,27H,1-2,5-11H2,(H2,22,26)/t16-,20-,21-/m1/s1
  • Key:RYIDHLJADOKWFM-MAODMQOUSA-N

Samidorphan (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name) (developmental code names ALKS-33, RDC-0313) is an opioid antagonist that in the form of olanzapine/samidorphan (brand name Lybalvi) is used in the treatment of schizophrenia and bipolar disorder.[1][3][4] Samidorphan reduces the weight gain associated with olanzapine.[5][6] Samidorphan is taken by mouth.[1][3]

Samidorphan was under development as a standalone medication for various indications but has been discontinued.[7] Buprenorphine/samidorphan for the treatment of major depressive disorder was rejected by the Food and Drug Administration due to insufficient evidence of effectiveness but remains in preregistration as of September 2021.[8] Development of baclofen/samidorphan has also been discontinued.[9]

Development

Samidorphan has been investigated for the treatment of alcoholism and cocaine addiction by its developer, Alkermes,[10][11] showing similar efficacy to naltrexone but possibly with reduced side effects.

However, it has attracted much more attention as part of the combination product ALKS-5461 (buprenorphine/samidorphan), where samidorphan is combined with the mixed μ-opioid receptor (MOR) weak partial agonist and κ-opioid receptor (KOR) antagonist buprenorphine, as an antidepressant. Buprenorphine has shown antidepressant effects in some human studies, thought to be because of its antagonist effects at the KOR, but has not been further developed for this application because of its MOR agonist effects and consequent abuse potential. By combining buprenorphine with samidorphan to block the MOR agonist effects, the combination acts more like a selective KOR antagonist, and produces only antidepressant effects, without typical MOR effects such as euphoria or substance dependence being evident.[12][13]

Samidorphan was also studied in combination with olanzapine, as ALKS-3831 (olanzapine/samidorphan), for use in schizophrenia.[14] A Phase 3 study found that the addition of samidorphan to olanzapine significantly reduced weight gain compared to olanzapine alone,[15] and the combination was approved for the treatment of schizophrenia and bipolar disorder by the US Food and Drug Administration in May 2021, under the brand name Lybalvi.[16][17]

Side effects

Side effects of samidorphan include somnolence and gastrointestinal disturbances among others.[1]

Pharmacology

Pharmacodynamics

Samidorphan at the opioid receptors[18][19]
Receptor Ki EC50 Emax IC50 Imax
MORTooltip mu-Opioid receptor 0.052 nM – 3.8% 0.88 nM 92%
KORTooltip kappa-Opioid receptor 0.23 nM 3.3 nM 36% 38 nM 57%
DORTooltip delta-Opioid receptor 2.6 nM 1.5 nM 35% 6.9 nM 56%

Samidorphan acts primarily as an antagonist or very weak partial agonist of the μ-opioid receptor (MOR) and to a lesser extent as a partial agonist of the κ-opioid receptor (KOR) and δ-opioid receptor (DOR).[1][18][19] In accordance with this profile, samidorphan has been observed to produce some side effects that are potentially consistent with activation of the KOR such as somnolence, sedation, dizziness, and hallucinations in some patients in clinical trials.[20]

Pharmacokinetics

The elimination half-life of samidorphan is 7 to 9 hours.[1][2]

Chemistry

Samidorphan has its origins in academia where 8-carboxamidocyclazocine and naltrexone were utilized in its design and synthesis.[21]

References

  1. ^ a b c d e f Chaudhary AM, Khan MF, Dhillon SS, Naveed S (July 2019). "A Review of Samidorphan: A Novel Opioid Antagonist". Cureus. 11 (7): e5139. doi:10.7759/cureus.5139. PMC 6741386. PMID 31523568.
  2. ^ a b Turncliff R, DiPetrillo L, Silverman B, Ehrich E (February 2015). "Single- and multiple-dose pharmacokinetics of samidorphan, a novel opioid antagonist, in healthy volunteers". Clinical Therapeutics. 37 (2): 338–348. doi:10.1016/j.clinthera.2014.10.001. PMID 25456560.
  3. ^ a b "LYBALVI: Highlight of Prescribing Information" (PDF). U.S. Food and Drug Administration.
  4. ^ "Olanzapine/samidorphan - Alkermes plc". Adis Insight. Springer Nature Switzerland AG.
  5. ^ Citrome L, Graham C, Simmons A, Jiang Y, Todtenkopf MS, Silverman B, et al. (2021). "An Evidence-Based Review of OLZ/SAM for Treatment of Adults with Schizophrenia or Bipolar I Disorder". Neuropsychiatric Disease and Treatment. 17: 2885–2904. doi:10.2147/NDT.S313840. PMC 8437420. PMID 34526769.
  6. ^ Paik J (August 2021). "Olanzapine/Samidorphan: First Approval". Drugs. 81 (12): 1431–1436. doi:10.1007/s40265-021-01568-0. PMID 34304374. S2CID 236215923.
  7. ^ "Samidorphan". Adis Insight. Springer Nature Switzerland AG.
  8. ^ "Buprenorphine/samidorphan - Alkermes". Adis Insight. Springer Nature Switzerland AG.
  9. ^ "Baclofen/samidorphan". Adis Insight. Springer Nature Switzerland AG.
  10. ^ Hillemacher T, Heberlein A, Muschler MA, Bleich S, Frieling H (August 2011). "Opioid modulators for alcohol dependence". Expert Opinion on Investigational Drugs. 20 (8): 1073–1086. doi:10.1517/13543784.2011.592139. PMID 21651459. S2CID 43338618.
  11. ^ Clinical trial number NCT01366001 for "ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With Cocaine" at ClinicalTrials.gov
  12. ^ "ALKS 5461 drug found to reduce depressive symptoms in Phase 1/2 study". 30 May 2012.
  13. ^ "Investigational ALKS 5461 Channels 'Opium Cure' for Depression".
  14. ^ LaMattina J (15 January 2013). "Will Alkermes' Antipsychotic ALKS-3831 Become Another Tredaptive?". Forbes.
  15. ^ Correll CU, Newcomer JW, Silverman B, DiPetrillo L, Graham C, Jiang Y, et al. (December 2020). "Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study". The American Journal of Psychiatry. 177 (12): 1168–1178. doi:10.1176/appi.ajp.2020.19121279. PMID 32791894. S2CID 221122225.
  16. ^ "Lybalvi: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 1 June 2021.
  17. ^ Ergenzinger, Ed. "New Antipsychotic Combo for Bipolar Disorder Approved by FDA | Psychology Today". www.psychologytoday.com. Retrieved 2021-07-24.
  18. ^ a b Linda P. Dwoskin (29 January 2014). Emerging Targets & Therapeutics in the Treatment of Psychostimulant Abuse. Elsevier Science. pp. 398–399, 402–403. ISBN 978-0-12-420177-4.
  19. ^ a b Wentland MP, Lou R, Lu Q, Bu Y, Denhardt C, Jin J, et al. (April 2009). "Syntheses of novel high affinity ligands for opioid receptors". Bioorganic & Medicinal Chemistry Letters. 19 (8): 2289–2294. doi:10.1016/j.bmcl.2009.02.078. PMC 2791460. PMID 19282177.
  20. ^ McElroy SL, Guerdjikova AI, Blom TJ, Crow SJ, Memisoglu A, Silverman BL, Ehrich EW (April 2013). "A placebo-controlled pilot study of the novel opioid receptor antagonist ALKS-33 in binge eating disorder". The International Journal of Eating Disorders. 46 (3): 239–245. doi:10.1002/eat.22114. PMID 23381803.
  21. ^ Wentland MP, Lu Q, Lou R, Bu Y, Knapp BI, Bidlack, JM (April 2005). "Synthesis and opioid receptor binding properties of a highly potent 4-hydroxy analogue of naltrexone". Bioorganic & Medicinal Chemistry Letters. 15 (8): 2107–10. doi:10.1016/j.bmcl.2005.02.032. PMID 15808478.
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Samidorphan&oldid=1203095627"